Boston Scientific Sees Robust Growth Driven by Strong Demand Across Key Segments

Boston Scientific (NYSE: BSX) is poised for robust growth in its Urology division, bolstered by the acquisition of medical technology firm Axonics (NASDAQ: AXNX), finalized in the fourth quarter of 2024. The segment, which contributes 13% of the company’s total revenue, is projected to grow +26% year-on-year in 2025, reaching $2.8 billion. By 2028, analysts anticipate Urology to become a key revenue driver within the company’s MedSurg segment.

Meanwhile, Boston Scientific’s core Cardiovascular division is set to benefit from strong demand for its Electrophysiology products, particularly the Farapulse pulsed-field ablation (PFA) system. The device, which received FDA approval in early 2024, is expected to drive revenue gains alongside Watchman, a stroke prevention implant. Cardiovascular revenue is forecast to rise 15% in 2025, reaching $12.4 billion.

The broader MedSurg segment—which includes Neuromodulation, Endoscopy, and Urology—is projected to expand by 13%, generating $6.8 billion in revenue. With momentum across key product lines, Boston Scientific is estimated to see continued top-line growth strengthening its position in the medical device industry.